Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine-primed Tandem CAR19/20 + Epigenetic Agents in Aggressive B-NHL
NCT04553393Phase 2Unknown
- Sponsor
- Chinese PLA General Hospital
- Start
- Sep 2020
- Primary completion
- Sep 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of decitabine-primed tandem CAR19/20 engineered T cells in B-cell non-Hodgkin lymphoma, sponsored by Chinese PLA General Hospital. Status: unknown.
02
Drugs
decitabine-primed tandem CAR19/20 engineered T cells
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT04553393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04553393.